Heparin is frequently used in neonatal intensive care units to prolong the patency of intravascular catheters. A study on patterns of drug use in newborn intensive care units in 1990 reported that heparin was used for 58% of newborn admissions (1). With the growing numbers of extremely low-birth-weight infants (ELBW), the need for central lines and the need for use of heparin to keep these catheters patent are on the rise. The safety profile and untoward effects of this frequently used medication in newborns have not been studied well. One of the poten-tially most devastating complications of heparin therapy is its propensity to cause thrombocytopenia with associated thrombosis (2).
Summary:
Heparin is frequently used in preterm infants to prolong the patency of intravascular catheters. The aim of this study was to evaluate the prevalence of heparin-dependent platelet-activating antibodies in newborns. A cross-section of all preterm newborn infants expected to require heparin to maintain patency of a central venous access line were enrolled. A blood sample was obtained soon after birth before heparin exposure to exclude the possibility of placental transfer of maternal heparin-dependent platelet-activating antibodies. A second sample was obtained at termination of heparin use (mean duration of heparin exposure was 23 ± 13 days; range, 6-67). Paired samples, at birth and after heparin use, were available for 42 infants with a mean gestational age of 27.8 ± 2.2 weeks and birth weight of 1036 ± 267 g. Thrombocytopenia developed in 57% (24/42) of the infants. None of these infants had clinical suspicion of thrombosis during the study period. The etiology of thrombocytopenia was confirmed sepsis in six, presumed sepsis in three, necrotizing enterocolitis in one, and unclear in 14 infants. Anti-heparin/platelet factor 4 antibodies measured using the standard assays for heparininduced thrombocytopenia (two commercially available enzymelinked immunosorbent assay tests and the functional platelet serotonin release assay) were negative on all infants. Although it could be related to the poor ability of these infants to mount an immunologic response, further research is necessary to fully understand this lack of response to heparin and to elucidate further the reasons for throm-to study the adult population. However, since the 1992 study of HIT in newborns, the clinical management of neonates, the clinical use of heparin, the frequency of HIT in the adult population, and the laboratory assays for HIT have changed, prompting interest for another study of HIT in neonates.
The prevalence of HIT and the impact of this problem on morbidity and mortality of newborns remain unknown. The aim of our study was to evaluate the prevalence of heparin-dependent platelet activating antibodies in preterm newborns exposed to unfractionated heparin. For this reason we selected a cross-section of newborn infants and did not study only those with symptoms of HIT.
METHODS
Over a 1-year period, all infants with a gestational age of 32 weeks or less, and/or with a birth weight of 1250 g or less were enrolled if expected to require heparin to maintain patency of central venous access lines. No other enrollment criteria were imposed to study the neonate population. An informed parental consent was obtained before enrollment. The study was approved by the Institutional Review Board of Northwestern Memorial Hospital.
The demographic data and a detailed maternal medical and obstetric history were obtained. A complete blood cell count including platelet count was obtained from the neonates soon after birth before exposure to heparin, at the end of the study, and as indicated during the study period. All patients had central vascular access lines. For patients in this study, the concentration of heparin in central line fluids was 1.0 U/mL and the intravenous heparin lock flushes contained 10 U/mL, with 0.6 mL administered every 6 hours. No patient experienced thrombosis of the vascular line. Porcine heparin was used in all infants and none of the infants received therapeutic anticoagulant doses of heparin.
A study blood sample was collected from the infants via the central catheter of the umbilical line at enrollment, before the infant was exposed to heparin. This sample served to exclude placental transfer of maternal antibodies. These samples were collected after drawing a discard sample and were free of heparin or other contamination. A second blood sample (exit sample) was collected either from a heel stick or venipuncture after heparin was discontinued.
Serum was separated soon after blood collection and all samples were stored at -80°C until analyzed.
Serum samples were evaluated for the presence of HIT antibodies with use of standard laboratory testing for HIT as used by clinical reference laboratories. Two commercially available enzyme-linked immunosorbent assay (ELISA) methods were used. The assay from GTI (Brookfield, WI) uses polyvinyl sulfonate-PF4 complex as the capture antigen (4). The assay from Diagnostica Stago (Parsippany, NJ) uses heparin-PF4 complex as the capture antigen (5, 6) .
The serotonin release assay (SRA), currently considered to be the best functional platelet activation test for HIT, was performed according to a previously described technique (7) . Briefly, the SRA is performed on washed platelets obtained from a normal donor who is known to be reactive in the assay. Patient serum, heated to destroy nonspecific enzymes, and heparin (final concentrations of 0, 0.1, and 100 U/mL) are added to the washed platelets that have been loaded with 14 C-radiolabeled serotonin. Heparin-dependent antibody in the patient serum activates the platelets in the presence of 0.1 U/mL heparin (in the range of the optimal antigen/antibody ratio), causing release of the 14 C-serotonin from the platelet granules. The assays for detection of HIT antibodies are technically demanding and require expert interpretation. All laboratory testing in this study was performed by a highly skilled laboratory staff that has been technically trained to perform these assays.
RESULTS
A total of 51 infants were enrolled in the study. Three infants did not receive heparin after enrollment, one infant died soon after enrollment, and five infants were transferred before the exit sample could be collected. Paired samples, at birth and after heparin use, were available for a total of 42 infants. Characteristics of study infants are described in Table 1 .
Thirty-six (86%) infants had a normal platelet count at birth and none of the infants had a platelet count less than 100 × 10 9 /L at birth ( Table 2 ). Thrombocytopenia (< 150 × 10 9 /L) developed in 24 (57%) infants while on heparin and 15 (36%) had a platelet count less than 100 × 10 9 /L ( Table 2 ). The etiology of thrombocytopenia in these infants was confirmed sepsis in six, presumed sepsis in three, necrotizing ente-rocolitis in one, and unclear in 14 (58%) infants. The mean age at the time of lowest platelet count was 7.4 ± 10.6 days. There were no episodes of clinical bleeding or thrombosis in any of the patients in this study.
ELISA test results were negative on all infants by both assays. Two infants had indeterminate results by SRA, meaning that there was platelet activation but that it was not heparin-dependent. This suggests that an anti-platelet antibody other than an HIT antibody was present. One of these two infants had thrombocytopenia.
DISCUSSION
Two types of HIT with distinct causes have been recognized. Type I HIT is characterized by a relatively mild thrombocytopenia that occurs during the first few days after the initiation of heparin therapy. The platelet count seldom drops below 100 × 10 9 /L and may return to normal levels without cessation of heparin. The patient usually remains asymptomatic. This type of HIT is presumed to be caused by an intrinsic proaggregatory effect of heparin. Type I HIT occurs in as many as 10% to 20% of patients exposed to heparin (8) .
Type II HIT is an immune reaction mediated by heparin-dependent platelet-activating antibodies that target a conformational change in PF4 induced when PF4 binds to heparin (2, 5, (9) (10) (11) . Via its Fab portion, the antibody binds to the complex of heparin/PF4, and via its Fc portion, the antibody binds to platelet FcγRIIa receptors. These interactions cause platelet activation, platelet aggregation, platelet destruction, a hypercoagulable state, and activation of the immune system (2, 9, (11) (12) (13) (14) (15) (16) . This leads to limb-or life-threatening thrombosis in one third of patients with HIT (17) . The incidence of HIT in adults is approximately 2% to 10% (8, 18, 19) . This incidence is not reported to correlate with age, gender, race, or underlying condition of the patient necessitating heparin use (8) . Several studies have reported that heparin-associated antibodies were detected with ELISA in approximately 10% to 25% of adult patients who re- ceived heparin for 3 to 5 days and in as many as 50% of patients if exposed for longer periods (7, 8, (20) (21) (22) . These studies indicated that although antibodies develop in many patients, only a portion of them will develop the clinical symptoms of thrombocytopenia with or without thrombosis. These studies indicate that unfractionated heparin is far more immunogenic in adults than has been appreciated.
The objective of our pilot study was to evaluate the prevalence of heparin-dependent plateletactivating antibodies in preterm newborns exposed to unfractionated heparin. We considered this important for two reasons: first, it could explain the etiology of thrombocytopenia in these infants; and second, the evidence of sensitization to heparin in the neonatal period will identify these patients to be at risk of developing complications after heparin exposure in future.
In the design of our study we included a blood sample collection from the infants at enrollment before being exposed to heparin. The purpose of this was to exclude the possibility of placental transfer of maternal HIT antibodies. HIT antibodies typically appear 4 to 5 days after heparin exposure and remain in circulation for approximately 3 months (2, 8, 9, 19) . Thus, our second sample from the infants was taken after discontinuation of heparin (a mean of 23 days; minimum of 6 days).
A variety of laboratory tests for the detection of heparin-dependent platelet antibodies have been described. A commonly used test is based on platelet aggregation as used in the earlier study on neonates by Spadone and colleagues (3) . This test suffers from a sensitivity as low as 60% and therefore was not used in our study (7, 20, 23, 24) . The currently accepted reference standard for the laboratory diagnosis of HIT is the two-point 14 C-serotonin release assay (SRA) because it is the most reliable test for confirming HIT (24, 25) . The SRA has a higher sensitivity of approximately 80% (25, 26) . It is nearly 100% specific for heparin antibody when performed as in this study (25) .
Recently, with the understanding of the antibody target, the ELISA technique has become available for the detection of HIT antibodies. These tests use either polyvinyl sulfonate-PF4 complex or PF4-heparin complex as the capture antigen. The sensitivity and specificity of these ELISAs has been reported to be 90% to 97% and 86% to 98%, respectively (25, 26) . Although the SRA and ELISA are reported to be useful for the laboratory diagnosis of HIT, approximately 10% of samples positive with SRA can have normal ELISA results and nearly the same percentage of samples negative with SRA can have unequivocally positive results with ELISA (26) . Thus, it is useful to perform both SRA and ELISA when testing for HIT.
It is for the purpose of having a comprehensive study that two commercially available ELISAs (as they have different specificities) (22) and the functional SRA test for HIT were included in our study. We sought to detect whether antibody was present using a sensitive test system but to also determine if these were clinically relevant HIT antibodies that were able to activate platelets in a heparin-dependent manner. In this first report on the prevalence of heparin-dependent platelet-activating antibodies in preterm newborns exposed to unfractionated heparin, none of the 42 infants that we studied had evidence of these antibodies after an average duration of 23 days of heparin exposure.
Although the reasons for lack of antibody production in these infants are not completely understood, various possibilities, including small sample size and small heparin dose, were considered. However, the statistical probability of seeing zero positive test in 42 infants is less than 1% based on observed rate (≥ 10%) of antibody production (isolated ELISA test positive) in adults (21, 27, 28) . Similarly, it is unlikely that the lack of antibody production was related to too small of a dose of heparin. Although we did not record the exact dose of heparin received by study infants, based on our unit protocol we estimated that study infants received heparin in the range of 40 to 150 U/kg per day during the study period. HIT has been reported in patients receiving any preparation of heparin, at any dose and by any route (9, 17, 19) . HIT has been reported in patients receiving a small amount of heparin in flush solutions used to maintain the patency of indwelling catheters and in patients with heparin-coated pulmonary artery catheters (9, 29) . Other possibilities for lack of antibody production in these infants include an immature immune system and the inherent differences in platelet structure or antigen expression of these preterm infants. Validation of these hypotheses will require further study.
In conclusion, the majority of preterm infants in our study had normal platelet counts at birth. Thrombocytopenia developed in nearly half of these infants during their stay in the NICU and the cause of thrombocytopenia was unclear in most of them. There was no evidence of heparin-dependent platelet-activating antibodies despite a significant duration of heparin exposure in the newborns. Although this study suggests that preterm infants may not generate heparin antibodies at the same frequency as adults, larger population studies are warranted.
